Development and validation of immunotherapy nomogram for predicting the efficacy and prognosis of recurrent and metastatic cervical cancer
These nomograms provide a reliable tool for predicting outcomes in cervical cancer immunotherapy, helping to personalize treatment and improve clinical management, especially for metastatic disease.
Authors
- Lihong He (ORCID: https://orcid.org/0000-0002-2694-2974)
- Daying Wu
- Sijia Zhang (ORCID: https://orcid.org/0000-0002-9718-7670)
- Zhongan Liu
- Tian Zhou (ORCID: https://orcid.org/0000-0001-5051-5182)
- Mulan Chen (ORCID: https://orcid.org/0000-0001-7854-0910)
- Yan Wang (ORCID: https://orcid.org/0000-0001-8990-5700)
- Guiling Li (ORCID: https://orcid.org/0000-0002-5663-4585)
- Yunqing Xu (ORCID: https://orcid.org/0009-0000-9435-1298)
- Kai Huang (ORCID: https://orcid.org/0000-0002-3725-7753)
- Guangqin Xiao
- Yan Zong (ORCID: https://orcid.org/0000-0002-9167-1859)
- Quan Tang
- Ganxin Wang
Institutions
- Harvard University (US)
- Osnabrück University (DE)
- Jianghan University (CN)
- Massachusetts General Hospital (US)
- The Central Hospital of Xiao gan (CN)
- Wuhan Union Hospital (CN)
- Hochschule Osnabrück (DE)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
- Hubei University (CN)
- Saarland University (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.3389/fimmu.2025.1662605
- Citations
- 1
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.06